ID

34199

Beschreibung

An Observational Study of Case Managed Versus Non-case Managed Initiation of Hemodialysis; ODM derived from: https://clinicaltrials.gov/show/NCT01613404

Link

https://clinicaltrials.gov/show/NCT01613404

Stichworte

  1. 15.01.19 15.01.19 -
Rechteinhaber

see on clinicaltrials.gov

Hochgeladen am

15. Januar 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Chronic Kidney Disease NCT01613404

Eligibility Chronic Kidney Disease NCT01613404

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients who initiated hemodialysis and expected to be on hemodialysis for at least 1 year
Beschreibung

ID.1

Datentyp

boolean

patients initiating hemodialysis requiring treatment (erythropoiesis stimulating agent or red blood cell transfusion) to correct the anemia of chronic kidney disease who are receiving erythropoiesis stimulating agent treatment at study entry or patients who do not require erythropoiesis stimulating agent therapy (hb within or above target range)
Beschreibung

ID.2

Datentyp

boolean

life expectancy should be more than 12 months
Beschreibung

ID.3

Datentyp

boolean

Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients contraindicated to receive erythropoiesis stimulating agent therapy (including but not limited to patients who develop pure red cell aplasia following treatment with any erythropoiesis stimulating agent )
Beschreibung

ID.4

Datentyp

boolean

patients entering the study on any other agent to increase red blood cell mass (such as androgen therapy, or investigational agents, or other non-approved erythropoiesis stimulating agent)
Beschreibung

ID.5

Datentyp

boolean

patients unwilling or unable to receive erythropoiesis stimulating agent therapy to correct the anemia of chronic kidney disease
Beschreibung

ID.6

Datentyp

boolean

patients with uncontrolled hypertension
Beschreibung

ID.7

Datentyp

boolean

patients who for any reason cannot receive adequate antithrombotic treatment
Beschreibung

ID.8

Datentyp

boolean

Ähnliche Modelle

Eligibility Chronic Kidney Disease NCT01613404

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
patients who initiated hemodialysis and expected to be on hemodialysis for at least 1 year
boolean
ID.2
Item
patients initiating hemodialysis requiring treatment (erythropoiesis stimulating agent or red blood cell transfusion) to correct the anemia of chronic kidney disease who are receiving erythropoiesis stimulating agent treatment at study entry or patients who do not require erythropoiesis stimulating agent therapy (hb within or above target range)
boolean
ID.3
Item
life expectancy should be more than 12 months
boolean
Item Group
C0680251 (UMLS CUI)
ID.4
Item
patients contraindicated to receive erythropoiesis stimulating agent therapy (including but not limited to patients who develop pure red cell aplasia following treatment with any erythropoiesis stimulating agent )
boolean
ID.5
Item
patients entering the study on any other agent to increase red blood cell mass (such as androgen therapy, or investigational agents, or other non-approved erythropoiesis stimulating agent)
boolean
ID.6
Item
patients unwilling or unable to receive erythropoiesis stimulating agent therapy to correct the anemia of chronic kidney disease
boolean
ID.7
Item
patients with uncontrolled hypertension
boolean
ID.8
Item
patients who for any reason cannot receive adequate antithrombotic treatment
boolean

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video